An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
NCT03154437
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Interventions
BIOLOGICAL:
Emicizumab
Sponsor
Genentech, Inc.